De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer

Endometrial Cancer Clinical Trial

— DeCRESCEndo  

Official title:

De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer (DeCRESCEndo)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04386993
• Other study ID #: 202004237
• Status: Recruiting
• Phase: Phase 1
• Start date: July 7, 2020
• Est. completion date: August 31, 2025

Study information

• Verified date: October 2023
• Source: Washington University School of Medicine
• Contact: Jessika Contreras, M.D.
• Phone: 314-747-7236
• Email: jcontreras[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: August 31, 2025
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed stage IIIA-IVA endometrial cancer, or any stage I-IVA where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology.

• Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.

• At least 18 years of age.

• ECOG performance status = 2

• Minimal bone marrow and organ function as defined below:

• Leukocytes = 1,000 cumm

• Absolute neutrophil count = 500 cumm

• Platelets = 50,000 cumm

• Hemoglobin = 7g/dL

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Prior radiation to the pelvis.

• Currently receiving any investigational agents.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease.

• Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms

Intervention

Radiation:
• Intensity modulated radiation therapy
Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of acute hematologic, gastrointestinal, and genitourinary adverse events		From start of radiation through Day 90
Primary	Incidence of late hematologic, gastrointestinal, and genitourinary adverse events		From Day 91 through month 12
Secondary	Change in patient-reported urinary and gastrointestinal toxicity as measured by PRO-CTCAE	PRO-CTCAE responses are scored from 0 to 4 with 0=Never/Not at all/None and 4=Frequently/Very Much/Very Severe/Almost Constantly; Scores for each attribute (frequency, severity and/or interference) will be presented descriptively	Baseline, 2 weeks, and 3 months post-completion of radiation
Secondary	Change in patient-reported urinary and gastrointestinal toxicity as measured by bowel/bladder domains of EPIC-26	Bladder has 7 questions and bowel has 9 questions; The response for each item is standardized to a 0 to 100 scale; The standardized values will be averaged for all items within a group to create the summary or subscale score.	Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
Secondary	Change in quality of life as measured by FACT-En	Questionnaire asking questions about physical well-being, social/family well-being, emotional well-being, functional well-being, and other additional concerns. Answers range from 0 = not at all to 4 = very much. Questions are phrased so that higher numbers indicate a better health state,; Scoring is performed through a simple sum of item scores. Each subscale is scored, and a total score is obtained by adding each of the subscale scores.	Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
Secondary	Locoregional control	-Locoregional recurrence is defined as histologic or radiographic evidence of cancer in the previously resected site or regional lymph nodes included in the radiated field.	Up to 12 months post-completion of radiation
Secondary	Distant control	-Distant recurrence is defined as histologic or radiographic evidence of cancer outside of the radiated field.	Up to 12 months post-completion of radiation
Secondary	Disease-free survival	-Disease-free survival is defined as survival with no evidence of disease recurrence or death	Up to 12 months post-completion of radiation
Secondary	Overall survival	-Number of participants alive at the time of completion of follow-up	Up to 12 months post-completion of radiation

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine